{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:58:02Z","timestamp":1791223082753,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.sapharm.2026.07.011","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:29:25Z","timestamp":1785367765000},"page":"1061-1074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The prevalence and impact of medication-related harm in people living with dementia \u2212 a systematic review and meta-analysis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9176-2669","authenticated-orcid":false,"given":"Fiona","family":"Carabine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4656-6021","authenticated-orcid":false,"given":"Carmel M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9684-8182","authenticated-orcid":false,"given":"Heather E.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2026.07.011_bib1","author":"Wittenberg"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib2","first-page":"79","article-title":"Dementia","volume":"84","author":"Cunningham","year":"2015","journal-title":"Ulst Med J"},{"key":"10.1016\/j.sapharm.2026.07.011_bib5","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1111\/jgs.17291","article-title":"Polypharmacy among older adults with dementia compared with those without dementia in the United States","volume":"69","author":"Growdon","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/1060028020949125","article-title":"Outcomes of medication misadventure among people with cognitive impairment or dementia: a systematic review and meta-analysis","volume":"55","author":"Zaidi","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.sapharm.2026.07.011_bib7","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jamda.2022.01.083","article-title":"Prevalence and risk factors for drug-related problems in people with dementia living in the community: a systematic review and meta-analysis","volume":"23","author":"Lau","year":"2022","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.sapharm.2026.07.011_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bcp.14417","article-title":"Prevalence of adverse drug events and adverse drug reactions in hospital among older patients with dementia: a systematic review","volume":"87","author":"Sakiris","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3233\/JAD-240575","article-title":"Prevalence of potentially inappropriate medications in older adults with cognitive impairment or dementia attending memory clinics: a systematic review and meta-analysis","volume":"101","author":"Sharma","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.sapharm.2026.07.011_bib10","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.sapharm.2026.07.011_bib11","author":"Higgins"},{"key":"10.1016\/j.sapharm.2026.07.011_bib12","series-title":"Endnote 20","year":"2013"},{"key":"10.1016\/j.sapharm.2026.07.011_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ Int"},{"key":"10.1016\/j.sapharm.2026.07.011_bib14","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1192\/bjb.2017.10","article-title":"Completed audit cycle to explore the use of the STOPP\/START toolkit to optimise medication in psychiatric in-patients with dementia","volume":"42","author":"Aziz","year":"2018","journal-title":"BJPsych Bull"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","article-title":"The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial","volume":"8","author":"Ballard","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.sapharm.2026.07.011_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40360-017-0142-9","article-title":"Psychotropic drug use and mortality in old people with dementia: investigating sex differences","volume":"18","author":"Br\u00e4nnstr\u00f6m","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.sapharm.2026.07.011_bib19","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/ene.14252","article-title":"Increased risk of death associated with the use of proton\u2010pump inhibitors in patients with dementia and controls - a pharmacoepidemiological claims data analysis","volume":"27","author":"Cetin","year":"2020","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.sapharm.2026.07.011_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004124","article-title":"Association between antidementia medication use and mortality in people diagnosed with dementia with lewy bodies in the UK: a retrospective cohort study","volume":"19","author":"Chen","year":"2022","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.sapharm.2026.07.011_bib21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00228-010-0828-z","article-title":"Profile of atypical antipsychotics use in patients affected by dementia in the University Hospital of Ferrara","volume":"66","author":"Chiabrando","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ageing\/afaa147","article-title":"Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes","volume":"50","author":"Delgado","year":"2021","journal-title":"Age Ageing"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jamda.2019.08.006","article-title":"Cognitive outcomes of long-term benzodiazepine and related drug (BDZR) use in people living with mild to moderate Alzheimer's disease: results from NILVAD","volume":"21","author":"Dyer","year":"2020","journal-title":"J Am Med Dir Assoc"},{"issue":"11","key":"10.1016\/j.sapharm.2026.07.011_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40266-020-00800-y","article-title":"Sedative load in community-dwelling older adults with mild-moderate Alzheimer's disease: longitudinal relationships with adverse events, delirium and falls","volume":"37","author":"Dyer","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.sapharm.2026.07.011_bib25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s41999-023-00910-x","article-title":"Long-term antipsychotic use, orthostatic hypotension and falls in older adults with Alzheimer's disease","volume":"15","author":"Dyer","year":"2024","journal-title":"Eur Geriatr Med"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib26","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3233\/JAD-170371","article-title":"Drugs for dementia and excess of hospitalization: a longitudinal French study","volume":"61","author":"Fran\u00e7ois","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/geriatrics9020028","article-title":"Deprescribing in older poly-treated patients affected with dementia","volume":"9","author":"Gareri","year":"2024","journal-title":"Geriatrics"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083224","article-title":"Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer's disease: a national population cohort study","volume":"9","author":"Gnjidic","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib29","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3233\/JAD-181295","article-title":"Hospital-treated pneumonia associated with opioid use among community dwellers with Alzheimer's disease","volume":"69","author":"Hamina","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00004850-200507000-00006","article-title":"The use of psychotropics and survival in demented elderly individuals","volume":"20","author":"Hartikainen","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.sapharm.2026.07.011_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13195-024-01481-0","article-title":"Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study","volume":"16","author":"Havreng-Th\u00e9ry","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"10.1016\/j.sapharm.2026.07.011_bib32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/1060028017708394","article-title":"Incident use of a potentially inappropriate medication and hip fracture in community-dwelling older persons with Alzheimer's disease","volume":"51","author":"Hyttinen","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jagp.2017.08.005","article-title":"Reduction of the anticholinergic burden makes it possible to decrease behavioral and psychological symptoms of dementia","volume":"26","author":"Ja\u00efdi","year":"2018","journal-title":"Am J Geriatr Psychiatr"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3233\/JAD-180125","article-title":"Hospitalization after oral antibiotic initiation in Finnish community dwellers with and without Alzheimer's disease: retrospective register-based cohort study","volume":"64","author":"J\u00e4rvinen","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"10.1016\/j.sapharm.2026.07.011_bib35","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.euroneuro.2015.08.014","article-title":"Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study","volume":"25","author":"Jennum","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"10.1016\/j.sapharm.2026.07.011_bib36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40266-014-0206-0","article-title":"Adverse drug reactions in elderly subjects hospitalized in a specialized dementia management unit","volume":"31","author":"Kanagaratnam","year":"2014","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4088\/JCP.15m10458","article-title":"Antipsychotic use and the risk of hip fracture among community-dwelling persons with Alzheimer's disease","volume":"78","author":"Koponen","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3233\/JAD-160671","article-title":"Risk of mortality associated with antipsychotic monotherapy and polypharmacy among community-dwelling persons with Alzheimer's disease","volume":"56","author":"Koponen","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.sapharm.2026.07.011_bib39","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jamda.2021.09.036","article-title":"Antipsychotic use and risk of stroke among community-dwelling people with Alzheimer's disease","volume":"23","author":"Koponen","year":"2022","journal-title":"J Am Med Dir Assoc"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jagp.2013.06.007","article-title":"Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study","volume":"22","author":"Langballe","year":"2014","journal-title":"Am J Geriatr Psychiatr"},{"issue":"9","key":"10.1016\/j.sapharm.2026.07.011_bib41","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/pds.3471","article-title":"Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study","volume":"22","author":"Laroche","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/jnnp.2006.094342","article-title":"Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer\u2019s disease longitudinal study","volume":"78","author":"Livingston","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.sapharm.2026.07.011_bib43","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jamda.2021.12.038","article-title":"Sedation-associated medications at dementia diagnosis, their receptor activity, and associations with adverse outcomes in a large clinical cohort","volume":"23","author":"Mbazira","year":"2022","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib44","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3233\/JAD-190751","article-title":"Factors associated with mortality including nursing home transitions: a retrospective analysis of 25,418 people prescribed anti-dementia drugs in Northern Ireland","volume":"73","author":"McMichael","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.sapharm.2026.07.011_bib45","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1080\/13607863.2020.1830028","article-title":"Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland","volume":"25","author":"McMichael","year":"2021","journal-title":"Aging Ment Health"},{"key":"10.1016\/j.sapharm.2026.07.011_bib46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12916-025-03851-3","article-title":"Antidepressant use and cognitive decline in patients with dementia: a national cohort study","volume":"23","author":"Mo","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.sapharm.2026.07.011_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076268","article-title":"Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study","volume":"385","author":"Mok","year":"2024","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.sapharm.2026.07.011_bib48","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jamda.2017.07.001","article-title":"Associations of neuropsychiatric symptoms and antidepressant prescription with survival in Alzheimer's disease","volume":"18","author":"Mueller","year":"2017","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.sapharm.2026.07.011_bib49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.exger.2018.02.011","article-title":"Polypharmacy in people with dementia: associations with adverse health outcomes","volume":"106","author":"Mueller","year":"2018","journal-title":"Exp Gerontol"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10654-020-00643-2","article-title":"Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes","volume":"36","author":"Mueller","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.sapharm.2026.07.011_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1472932","article-title":"Patients with dementia: prevalence and type of drug\u2013drug interactions","volume":"15","author":"Mu\u00f1oz-Contreras","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib52","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/ageing\/afaa067","article-title":"Potentially inappropriate medication use in older adults with mild-moderate Alzheimer's disease: prevalence and associations with adverse events","volume":"49","author":"Murphy","year":"2020","journal-title":"Age Ageing"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000326213","article-title":"Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease","volume":"31","author":"Musicco","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib54","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12828","article-title":"Association of benzodiazepines and antidepressants with 180-day mortality among patients with dementia receiving antipsychotic pharmacotherapy","volume":"81","author":"N\u00f8rgaard","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.sapharm.2026.07.011_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamda.2013.03.014","article-title":"Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: results from the Shelter Study","volume":"14","author":"Onder","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.sapharm.2026.07.011_bib56","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/CLEP.S278306","article-title":"Hip fracture risk in antiepileptic drug initiators and non-initiators with Alzheimer's disease","volume":"13","author":"Pisa","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.sapharm.2026.07.011_bib57","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1002\/alz.13012","article-title":"Impact of low\u2010value medications on quality of life, hospitalization and costs - a longitudinal analysis of patients living with dementia","volume":"19","author":"Platen","year":"2023","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.sapharm.2026.07.011_bib58","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1159\/000538074","article-title":"Short-term medication effect on fall risk in multimorbid inpatients with dementia","volume":"70","author":"Podesser","year":"2024","journal-title":"Gerontology"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib59","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00228-013-1588-3","article-title":"Predictors of mortality in atypical antipsychotic-treated community-dwelling elderly patients with behavioural and psychological symptoms of dementia: a prospective population-based cohort study from Italy","volume":"70","author":"Rafaniello","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.sapharm.2026.07.011_bib60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ehjcvp\/pvae091","article-title":"Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure","volume":"11","author":"Reimers-Wessberg","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ageing\/afx147","article-title":"Potentially inappropriate medication among people with dementia in eight European countries","volume":"47","author":"Renom-Guiteras","year":"2018","journal-title":"Age Ageing"},{"key":"10.1016\/j.sapharm.2026.07.011_bib62","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12916-020-01821-5","article-title":"Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study","volume":"18","author":"Richardson","year":"2020","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib63","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/gps.4821","article-title":"Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: a matched cohort study","volume":"33","author":"Saarelainen","year":"2017","journal-title":"Int J Geriatr Psychiatr"},{"issue":"20","key":"10.1016\/j.sapharm.2026.07.011_bib64","first-page":"e2099","article-title":"Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease","volume":"94","author":"Sarycheva","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib65","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jamda.2018.12.019","article-title":"Antipsychotic treatment associated with increased mortality risk in patients with dementia. A registry-based observational cohort study","volume":"20","author":"Schwertner","year":"2019","journal-title":"J Am Med Dir Assoc"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib66","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ehjcvp\/pvad102","article-title":"Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction","volume":"10","author":"Shahim","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"10","key":"10.1016\/j.sapharm.2026.07.011_bib67","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00228-018-2514-5","article-title":"Clinically relevant drug-drug interactions among elderly people with dementia","volume":"74","author":"S\u00f6nnerstam","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.sapharm.2026.07.011_bib68","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.exger.2019.02.019","article-title":"The relationship between polypharmacy and trajectories of cognitive decline in people with dementia: a large representative cohort study","volume":"120","author":"Soysal","year":"2019","journal-title":"Exp Gerontol"},{"issue":"6","key":"10.1016\/j.sapharm.2026.07.011_bib69","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/0091270011405665","article-title":"New insights: Dose-response relationship between psychotropic drugs and falls: a study in nursing home residents with dementia","volume":"52","author":"Sterke","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.sapharm.2026.07.011_bib70","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1365-2125.2011.04124.x","article-title":"Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia","volume":"73","author":"Sterke","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/YIC.0000000000000161","article-title":"Use of benzodiazepines and related drugs is associated with a risk of stroke among persons with Alzheimer's disease","volume":"32","author":"Taipale","year":"2017","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.sapharm.2026.07.011_bib72","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13195-017-0285-3","article-title":"Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer's disease: a nationwide matched cohort study","volume":"9","author":"Taipale","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"14","key":"10.1016\/j.sapharm.2026.07.011_bib73","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1503\/cmaj.160126","article-title":"Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease","volume":"189","author":"Taipale","year":"2017","journal-title":"Can Med Assoc J"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JAD-180912","article-title":"Antiepileptic drug use is associated with an increased risk of pneumonia among community-dwelling persons with Alzheimer's disease-matched cohort study","volume":"68","author":"Taipale","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"10.1016\/j.sapharm.2026.07.011_bib75","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00198-019-04957-0","article-title":"Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer's disease - nested case-control study","volume":"30","author":"Taipale","year":"2019","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib76","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/jgs.16275","article-title":"The risk of head injuries associated with antipsychotic use among persons with Alzheimer's disease","volume":"68","author":"Tapiainen","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"10.1016\/j.sapharm.2026.07.011_bib77","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.chest.2016.06.004","article-title":"Antipsychotic use and risk of hospitalization or death due to pneumonia in persons with and those without Alzheimer disease","volume":"150","author":"Tolppanen","year":"2016","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.sapharm.2026.07.011_bib78","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/pds.4232","article-title":"Screening approach for identifying candidate drugs and drug-drug interactions related to hip fracture risk in persons with Alzheimer disease","volume":"26","author":"Tolppanen","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"10.1016\/j.sapharm.2026.07.011_bib79","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1002\/gps.4667","article-title":"Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer's disease","volume":"32","author":"Torvinen-Kiiskinen","year":"2017","journal-title":"Int J Geriatr Psychiatr"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib80","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000079201","article-title":"Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy","volume":"18","author":"Wallin","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib81","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3233\/JAD-190819","article-title":"Drug-related problems increase healthcare costs for people living with dementia","volume":"73","author":"Wohlgemuth","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"10.1016\/j.sapharm.2026.07.011_bib82","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.jamda.2020.11.013","article-title":"Changes in drug prescribing practices are associated with improved outcomes in patients with dementia in Sweden: experience from the Swedish Dementia Registry 2008-2017","volume":"22","author":"Xu","year":"2021","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib83","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.kint.2022.09.022","article-title":"Association between cholinesterase inhibitors and kidney function decline in patients with Alzheimer's dementia","volume":"103","author":"Xu","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.sapharm.2026.07.011_bib84","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.1002\/alz.14118","article-title":"Long\u2010term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: an up to 10\u2010year follow\u2010up study","volume":"20","author":"Xu","year":"2024","journal-title":"Alzheimer's Dement"},{"issue":"11","key":"10.1016\/j.sapharm.2026.07.011_bib85","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/gps.5587","article-title":"Risk of hospitalization and hip fracture associated with psychotropic polypharmacy in patients with dementia: a nationwide register\u2010based study","volume":"36","author":"Zakarias","year":"2021","journal-title":"Int J Geriatr Psychiatr"},{"issue":"6","key":"10.1016\/j.sapharm.2026.07.011_bib86","doi-asserted-by":"crossref","first-page":"549.e1","DOI":"10.1016\/j.jamda.2017.02.001","article-title":"Association between psychotropic and cardiovascular iatrogenic alerts and risk of hospitalizations in elderly people treated for dementia: a self-controlled case series study based on the matching of 2 French health insurance databases","volume":"18","author":"Zerah","year":"2017","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib87","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1177\/07334648211023678","article-title":"Potential side effects and adverse events of antipsychotic use for residents with dementia in assisted living: implications for prescribers, staff, and families","volume":"41","author":"Beeber","year":"2022","journal-title":"J Appl Gerontol"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.6061\/clinics\/2016(01)04","article-title":"Severe potential drug-drug interactions in older adults with dementia and associated factors","volume":"71","author":"Bogetti-Salazar","year":"2016","journal-title":"Clinics"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib89","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1017\/S104161020800803X","article-title":"Reduction of suboptimal prescribing and clinical outcome for dementia patients in a senior behavioral health inpatient unit","volume":"21","author":"Chan","year":"2009","journal-title":"Int Psychogeriatr"},{"issue":"10","key":"10.1016\/j.sapharm.2026.07.011_bib90","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1111\/jgs.18463","article-title":"Medication misuse and overuse in community\u2010dwelling persons with dementia","volume":"71","author":"Deardorff","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib91","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3928\/00989134-20130220-91","article-title":"Characterizing caregiver mediated medication management in patients with memory loss","volume":"39","author":"Erlen","year":"2013","journal-title":"J Gerontol Nurs"},{"issue":"5","key":"10.1016\/j.sapharm.2026.07.011_bib92","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1080\/13607860601086629","article-title":"High prevalence of central nervous system medications in community-dwelling older adults with dementia over a three-year period","volume":"11","author":"Fick","year":"2007","journal-title":"Aging Ment Health"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib93","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1017\/S1041610205002280","article-title":"Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics","volume":"17","author":"Finkel","year":"2005","journal-title":"Int Psychogeriatr"},{"issue":"9","key":"10.1016\/j.sapharm.2026.07.011_bib94","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","article-title":"Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study","volume":"169","author":"Gill","year":"2009","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.sapharm.2026.07.011_bib95","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40266-022-00991-6","article-title":"Hallucinations, antipsychotic use, and mortality in older adults with dementia: retrospective cohort study of two Medicare-linked National Health Surveys","volume":"39","author":"Hamedani","year":"2022","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.sapharm.2026.07.011_bib96","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/phar.2244","article-title":"The association between central nervous system-active medication use and fall-related injury in community-dwelling older adults with dementia","volume":"39","author":"Hart","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.sapharm.2026.07.011_bib97","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.apnu.2006.04.004","article-title":"Outcomes of antipsychotic drug use in community-dwelling elders with dementia","volume":"20","author":"Kolanowski","year":"2006","journal-title":"Arch Psychiatr Nurs"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib98","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-107-2-169","article-title":"Adverse drug reactions associated with global cognitive impairment in elderly persons","volume":"107","author":"Larson","year":"1987","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.sapharm.2026.07.011_bib99","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.amjopharm.2012.11.001","article-title":"Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex","volume":"10","author":"Marras","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"issue":"6","key":"10.1016\/j.sapharm.2026.07.011_bib100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40266-022-00944-z","article-title":"Risk of serious adverse events associated with individual cholinesterase inhibitors use in older adults with dementia: a population-based cohort study","volume":"39","author":"Masurkar","year":"2022","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.sapharm.2026.07.011_bib101","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.sapharm.2026.07.011_bib102","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jamda.2015.01.079","article-title":"Elevated hospitalization risk of assisted living residents with dementia in Alberta, Canada","volume":"16","author":"Maxwell","year":"2015","journal-title":"J Am Med Dir Assoc"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib103","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jgs.18108","article-title":"Benefits and harms of oral anticoagulants for atrial fibrillation in nursing home residents with advanced dementia","volume":"71","author":"Ouellet","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"10.1016\/j.sapharm.2026.07.011_bib104","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/archinternmed.2012.28","article-title":"Antipsychotic use and myocardial infarction in older patients with treated dementia","volume":"172","author":"Pariente","year":"2012","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jgs.12061","article-title":"Older men with dementia are at greater risk than women of serious events after initiating antipsychotic therapy","volume":"61","author":"Rochon","year":"2013","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"10.1016\/j.sapharm.2026.07.011_bib106","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1177\/1060028019866927","article-title":"Emergency department visits for psychotropic-related adverse drug events in older adults with Alzheimer disease, 2013-2014","volume":"53","author":"Sepassi","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib107","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/11599480-000000000-00000","article-title":"Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia \u2013 a population-based, cohort study","volume":"29","author":"Stephenson","year":"2012","journal-title":"Drugs Aging"},{"issue":"9","key":"10.1016\/j.sapharm.2026.07.011_bib108","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/MLR.0000000000001889","article-title":"Fall-related injuries and opioid administration among veterans with dementia in US Department of Veterans Affairs community living centers","volume":"61","author":"Wang","year":"2023","journal-title":"Med Care"},{"issue":"47","key":"10.1016\/j.sapharm.2026.07.011_bib109","doi-asserted-by":"crossref","first-page":"e1376","DOI":"10.1503\/cmaj.180551","article-title":"Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study","volume":"190","author":"Watt","year":"2018","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.sapharm.2026.07.011_bib110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12877-024-04949-8","article-title":"Potentially inappropriate prescribing for people with dementia in ambulatory care: a cross-sectional observational study","volume":"24","author":"Alageel","year":"2024","journal-title":"BMC Geriatr"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib111","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/gps.2347","article-title":"Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study","volume":"25","author":"Chan","year":"2010","journal-title":"Int J Geriatr Psychiatr"},{"issue":"23","key":"10.1016\/j.sapharm.2026.07.011_bib112","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000919","article-title":"Effect of psychotropic drugs on development of diabetes mellitus in patients with Alzheimer's disease","volume":"94","author":"Chang","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.sapharm.2026.07.011_bib113","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1038\/s41598-023-34173-0","article-title":"Relationship between antidementia medication and fracture prevention in patients with Alzheimer's dementia using a nationwide health insurance claims database","volume":"13","author":"Hosoi","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib114","doi-asserted-by":"crossref","first-page":"121","DOI":"10.12779\/dnd.2023.22.4.121","article-title":"Association between persistent treatment of Alzheimer's dementia and osteoporosis using a common data model","volume":"22","author":"Hwang","year":"2023","journal-title":"Dement Neurocogn Disord"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1253\/circrep.CR-20-0115","article-title":"Effect of QT prolongation in patients taking cholinesterase inhibitors (donepezil) for Alzheimer's disease","volume":"3","author":"Kuwahata","year":"2021","journal-title":"Circ Rep"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib116","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/JCP.0000000000000726","article-title":"Adverse events with sustained-release donepezil in Alzheimer disease","volume":"37","author":"Lee","year":"2017","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"10.1016\/j.sapharm.2026.07.011_bib117","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5414\/CP202361","article-title":"Prescription patterns of psychotropic medications and use of electroconvulsive therapy in Chinese patients with dementia","volume":"53","author":"Li","year":"2015","journal-title":"Int J Clin Pharm Ther"},{"key":"10.1016\/j.sapharm.2026.07.011_bib118","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s12877-024-05300-x","article-title":"Risk of falls or fall-related injuries associated with potentially inappropriate medication use among older adults with dementia","volume":"24","author":"Moon","year":"2024","journal-title":"BMC Geriatr"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib119","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/a-2184-7506","article-title":"Risk of incident atrial fibrillation and subsequent use of oral anticoagulants in patients with dementia","volume":"124","author":"Tsai","year":"2024","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/psyg.12291","article-title":"Risk of hospitalization associated with anticholinergic medication for patients with dementia","volume":"18","author":"Watanabe","year":"2018","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.sapharm.2026.07.011_bib121","article-title":"Impact of acetylcholinesterase inhibitors on the occurrence of acute coronary syndrome in patients with dementia","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.sapharm.2026.07.011_bib122","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/bcp.14345","article-title":"Potentially inappropriate medication use and related hospital admissions in aged care residents: the impact of dementia","volume":"86","author":"Eshetie","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib123","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40266-014-0230-0","article-title":"Impact of multiple low-level anticholinergic medications on anticholinergic load of community-dwelling elderly with and without dementia","volume":"32","author":"Mate","year":"2015","journal-title":"Drugs Aging"},{"issue":"7","key":"10.1016\/j.sapharm.2026.07.011_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236830","article-title":"Drug related problems in older adults living with dementia","volume":"15","author":"Ruangritchankul","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/agm2.12175","article-title":"A delicate balance: psychotropic polypharmacy and anti\u2010cholinergic use are correlated with fall incidence in Australian inpatients with dementia","volume":"4","author":"Tan","year":"2021","journal-title":"Aging Med"},{"issue":"7","key":"10.1016\/j.sapharm.2026.07.011_bib126","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jamda.2020.11.024","article-title":"Poisoning exposures in people with dementia (2014-2019): a retrospective study","volume":"22","author":"Wojt","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.sapharm.2026.07.011_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20420986221080796","article-title":"Ten-year trends in adverse drug reaction-related hospitalizations among people with dementia","volume":"13","author":"Zaidi","year":"2022","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/17512433.2023.2294007","article-title":"Adverse clinical outcomes associated with drug-related hospitalizations in people with dementia","volume":"17","author":"Zaidi","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.sapharm.2026.07.011_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.538095","article-title":"Frequency and severity of adverse drug reactions to medications prescribed for Alzheimer's disease in a Brazilian city: Cross-sectional study","volume":"11","author":"Ferreira","year":"2020","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.sapharm.2026.07.011_bib130","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025015","article-title":"Potentially inappropriate prescriptions to Brazilian older people with Alzheimer disease: a cross-sectional study","volume":"100","author":"Ferreira","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.sapharm.2026.07.011_bib131","series-title":"The Use of Antipsychotic Medication for People with Dementia: Time for Action","author":"Banerjee","year":"2009"},{"issue":"3","key":"10.1016\/j.sapharm.2026.07.011_bib132","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3233\/JAD-140579","article-title":"The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials","volume":"42","author":"Ma","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.sapharm.2026.07.011_bib133","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/acps.12614","article-title":"Cumulative dosages of antipsychotic drugs are associated with increased mortality rate in patients with Alzheimer's dementia","volume":"134","author":"Nielsen","year":"2016","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/ADR-170042","article-title":"Increased all-cause mortality by antipsychotic drugs: updated review and meta-Analysis in dementia and general mental health care","volume":"2","author":"Ralph","year":"2018","journal-title":"J Alzheimer\u2019s Dis Rep"},{"issue":"5","key":"10.1016\/j.sapharm.2026.07.011_bib135","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/JCP.0000000000001083","article-title":"Mortality risk of atypical antipsychotics for behavioral and psychological symptoms of dementia","volume":"39","author":"Yeh","year":"2019","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.sapharm.2026.07.011_bib136","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.289.2.210","article-title":"Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease","volume":"289","author":"Trinh","year":"2003","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"10.1016\/j.sapharm.2026.07.011_bib137","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline","volume":"148","author":"Raina","year":"2008","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.sapharm.2026.07.011_bib138","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/gps.3931","article-title":"Community pharmacists and people with dementia: a cross-sectional survey exploring experiences, attitudes, and knowledge of pain and its management","volume":"28","author":"Barry","year":"2013","journal-title":"Int J Geriatr Psychiatr"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib139","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12913-020-4971-7","article-title":"Improving medicines management for people with dementia in primary care: a qualitative study of healthcare professionals to develop a theory-informed intervention","volume":"20","author":"Barry","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.sapharm.2026.07.011_bib140","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1532-5415.2009.02617.x","article-title":"An evaluation of an adapted U.S. model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland (Fleetwood Northern Ireland Study)","volume":"58","author":"Patterson","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.sapharm.2026.07.011_bib141","first-page":"359","article-title":"Quality improvement in action antipsychotic prescribing in nursing homes: an audit report","volume":"17","author":"Morrison","year":"2009","journal-title":"Qual Prim Care"},{"issue":"12","key":"10.1016\/j.sapharm.2026.07.011_bib142","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/11318890-000000000-00000","article-title":"Interventions that can reduce inappropriate prescribing in the elderly","volume":"26","author":"Kaur","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.sapharm.2026.07.011_bib143","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40360-017-0157-2","article-title":"Drug-related problems and medication reviews among old people with dementia","volume":"18","author":"Pfister","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.sapharm.2026.07.011_bib144","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12877-018-1015-9","article-title":"Consensus and evidence-based medication review to optimize and potentially reduce psychotropic drug prescription in institutionalized dementia patients","volume":"19","author":"Massot Mesquida","year":"2019","journal-title":"BMC Geriatr"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741126001713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741126001713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:39:11Z","timestamp":1791221951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741126001713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":141,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1551741126001713"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2026.07.011","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prevalence and impact of medication-related harm in people living with dementia \u2212 a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2026.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}